Creative Planning’s Zentalis Pharmaceuticals ZNTL Stock Holding History

Creative Planning’s Portfolio ZNTL Stock Details ZNTL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$667K	Buy	285,000 +25,000	+10%	+$64.6K	﹤0.01%	2793
2025 Q4	$351K	Hold	260,000	–	–	﹤0.01%	3132
2025 Q3	$393K	Buy	260,000 +229,660	+757%	+$344K	﹤0.01%	2938
2025 Q2	$35.2K	Sell	30,340 -206,183	-87%	-$272K	﹤0.01%	3552
2025 Q1	$376K	Buy	236,523 +196,420	+490%	+$424K	﹤0.01%	2559
2024 Q4	$122K	Buy	40,103 +28,803	+255%	+$94.4K	﹤0.01%	3119
2024 Q3	$41.6K	Sell	11,300 -2,099	-16%	-$7.63K	﹤0.01%	3110
2024 Q2	$54.8K	Buy	13,399 +1,809	+16%	+$20.2K	﹤0.01%	2919
2024 Q1	$183K	Buy	11,590 +590	+5%	+$8.12K	﹤0.01%	2596
2023 Q4	$167K	Buy	+11,000	New	+$160K	﹤0.01%	2489

Other funds holding ZNTL

5VM

5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return

SCM

Squadron Capital Management Westmont, Illinois $273M AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return

Creative Planning's ZNTL Position: Q1 2026 in Review

Creative Planning increased its Zentalis Pharmaceuticals (ZNTL) stake by 9.6% in Q1 2026, buying an estimated $64.6K and bringing the position to 285,000 shares worth $667K. The position accounts for ﹤0.01% of the portfolio, ranked #2793.

Creative Planning first reported a position in ZNTL in Q4 2023 and has held it in 10 quarters since. 102 funds tracked by Wall St. Rank hold ZNTL as of Q1 2026.

Creative Planning held 285,000 shares of Zentalis Pharmaceuticals worth $667K as of Q1 2026.
Creative Planning bought 25,000 Zentalis Pharmaceuticals shares in Q1 2026, an estimated $64.6K.
Zentalis Pharmaceuticals made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #2793 holding.
Creative Planning first reported a position in Zentalis Pharmaceuticals in Q4 2023 and has held it in 10 quarters since.
102 funds tracked by Wall St. Rank held Zentalis Pharmaceuticals as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.